Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 16/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.75 |
| ▸ | GCGR | P47871 | 14/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.75 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.75 |
| ▸ | FRK | P42685 | 4/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.75 |
| ▸ | GSK3B | P49841 | 4/20 | 0.75 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.75 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.75 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.75 |
| ▸ | ALOX5 | P09917 | 13/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.67 |
| ▸ | CSNK1A1L | Q8N752 | 3/20 | 0.67 |
| ▸ | PRKACA | P17612 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9192799 | 1.00 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL27075368 | 1.00 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL95208 | 1.00 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL25800837 | 1.00 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL146399 | 1.00 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL4890447 | 0.99 | MAPK11 (0.73) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL20335254 | 0.90 | MAPK11 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6447875 | 0.89 | MAPK13 (0.72) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL1389121 | 0.87 | MAPK14 (0.67) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6606221 | 0.87 | MAPK11 (0.70) | MAPK11MAPK14MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070091-A1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2016-09-21 | — | — | EP | claimed |
| EP-2585469-B1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-05-25 | — | — | EP | claimed |
| EP-2114951-B9 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2015-09-02 | — | — | EP | claimed |
| US-8980905-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-03-17 | — | — | US | claimed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | claimed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | claimed |
| JP-2010513276-A | — | — | 2010-04-30 | — | — | JP | claimed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | claimed |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | claimed |
| CN-101657460-A | Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM' S) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction | GILEAD SCIENCES INC US | 2010-02-24 | — | — | CN | claimed |
| CN-101631792-A | Novel phosphodiesterase inhibitors | LEO PHARMA AS | 2010-01-20 | — | — | CN | claimed |
| EP-2125841-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND BETA-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | Gilead Sciences, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008076265-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-20040053833-A1 | Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-03-18 | — | — | US | claimed |
| EP-1332372-A2 | NET, A TRANSCRIPTION FACTOR OF THE TCF FAMILY, AS REGULATOR OF ANGIOGENIC FACTOR EXPRESSION | Aventis Pharma S.A. (FR) | 2003-08-06 | — | — | EP | claimed |
| WO-2002035235-A2 | NET AS REGULATOR OF ANGIOGENIC EXPRESSION | AVENTIS PHARMA S.A. (FR) | 2002-05-02 | — | — | WO | claimed |
| EP-1202065-A1 | Net, a transcription factor of the TCF family, as regulator of angiogenic expression. | Aventis Pharma S.A. (FR) | 2002-05-02 | — | — | EP | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2002035235-A2 | NET AS REGULATOR OF ANGIOGENIC EXPRESSION | AVENTIS PHARMA S.A. (FR) | 2002-05-02 | — | — | WO | disclosed |
| EP-1202065-A1 | Net, a transcription factor of the TCF family, as regulator of angiogenic expression. | Aventis Pharma S.A. (FR) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | MAPK11 1946/4885MAPK14 3216/4885MAPK13 1875/4885 |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE5A, PDE3B | MAPK11 2920/4885MAPK14 3778/4885MAPK13 2984/4885 |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | MAPK11 734/4885MAPK14 1362/4885MAPK13 836/4885 |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | MAPK11 2592/4885MAPK14 2437/4885MAPK13 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.